Numeric Investors LLC Raises Holdings in Vanda Pharmaceuticals Inc. (VNDA)
Numeric Investors LLC boosted its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 59.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 228,900 shares of the biopharmaceutical company’s stock after acquiring an additional 85,700 shares during the quarter. Numeric Investors LLC owned about 0.51% of Vanda Pharmaceuticals worth $3,731,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of VNDA. Point72 Asset Management L.P. raised its position in Vanda Pharmaceuticals by 1,544.3% in the first quarter. Point72 Asset Management L.P. now owns 2,484,500 shares of the biopharmaceutical company’s stock worth $34,783,000 after acquiring an additional 2,333,400 shares in the last quarter. FMR LLC raised its position in Vanda Pharmaceuticals by 60.7% in the first quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock worth $22,416,000 after acquiring an additional 604,900 shares in the last quarter. Vanguard Group Inc. raised its position in Vanda Pharmaceuticals by 26.4% in the first quarter. Vanguard Group Inc. now owns 2,494,347 shares of the biopharmaceutical company’s stock worth $34,920,000 after acquiring an additional 521,669 shares in the last quarter. Nexthera Capital LP bought a new stake in Vanda Pharmaceuticals in the first quarter worth about $7,171,000. Finally, Renaissance Technologies LLC raised its position in Vanda Pharmaceuticals by 65.3% in the first quarter. Renaissance Technologies LLC now owns 939,250 shares of the biopharmaceutical company’s stock worth $13,150,000 after acquiring an additional 370,900 shares in the last quarter. Hedge funds and other institutional investors own 86.49% of the company’s stock.
Several brokerages have commented on VNDA. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $21.00 price target on shares of Vanda Pharmaceuticals in a research report on Thursday, September 14th. Piper Jaffray Companies boosted their price target on shares of Vanda Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Thursday, September 14th. Jefferies Group LLC reiterated a “buy” rating and issued a $21.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, August 29th. Finally, BidaskClub upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $21.63.
TRADEMARK VIOLATION NOTICE: This news story was published by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/numeric-investors-llc-raises-holdings-in-vanda-pharmaceuticals-inc-vnda/1610027.html.
Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) opened at 18.00 on Thursday. The firm’s market cap is $807.44 million. Vanda Pharmaceuticals Inc. has a 12-month low of $12.70 and a 12-month high of $18.99. The firm’s 50-day moving average price is $17.34 and its 200 day moving average price is $15.52.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The firm had revenue of $42.06 million for the quarter, compared to analysts’ expectations of $40.31 million. During the same quarter last year, the business earned $0.01 earnings per share. The company’s revenue was up 16.7% compared to the same quarter last year. On average, equities analysts expect that Vanda Pharmaceuticals Inc. will post ($0.42) earnings per share for the current fiscal year.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.